Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II)

✍ Scribed by Dr. Jay E. Gold; Ira J. Bleiweiss; Alisan B. Goldfarb; Joel J. Bauer; Irwin M. Gelernt; Myron E. Schwartz; Mark A. Reiner; Charles M. Miller; Marshall F. Weiss; Steven T. Brower; Ted R. Masters; Michael E. Osband

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 677 KB
• Volume: 55
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930550405

✦ Synopsis

Autolymphocyte therapy (ALT) is adoptive cellular therapy of cancer using ex vivo activation of autologous peripheral blood lymphocytes (PBL). Memory T cells are the principal effector population in ALT, with in vivo activity in patients with metastatic renal cell carcinoma (RCC) and melanoma, and ex vivo cytotoxicity against autologous tumor targets. However, the noncytolytic lymphocyte portion of ex vivo-activated memory T cells (ALT cells) may also contribute as antitumor effectors. Pretreatment of murine and human tumor cells ex vivo with chemotherapeutic agents can enhance their susceptibility to antitumor lymphocytes ex vivo and in vivo. To determine whether cis-diamminedichloroplatinum(I1) (DDP) could enhance ex vivo antitumor effects of ALT cells by immunomodulation, human breast and colorectal carcinoma target cells were derived from both primary and metastatic surgical specimens and incubated in complete medium (CM) with DDP or in CM alone (control group). Viability of each group was confirmed by trypan blue-dye exclusion test. ALT cells were prepared from autologous PBL at surgery. Primary and metastatic tumor cells from each group were used as targets for ALT cells and levels of interferon-y (IFN-y) release were measured as a determination of antitumor effect and recognition. Primary tumor target cells incubated in DDP showed enhanced antitumor effects and recognition by autologous ALT cells, as measured by the IFN-y assay compared to non-DDP-treated controls. Metastatic autologous tumor target cells demonstrated less IFN-y release than did the primary targets, although this was enhanced by pre-treating metastatic tumor targets with DDP. ALT cells